Literature DB >> 21495058

Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.

Alexandra C Graf1, Peter Bauer.   

Abstract

We calculate the maximum type 1 error rate of the pre-planned conventional fixed sample size test for comparing the means of independent normal distributions (with common known variance) which can be yielded when sample size and allocation rate to the treatment arms can be modified in an interim analysis. Thereby it is assumed that the experimenter fully exploits knowledge of the unblinded interim estimates of the treatment effects in order to maximize the conditional type 1 error rate. The 'worst-case' strategies require knowledge of the unknown common treatment effect under the null hypothesis. Although this is a rather hypothetical scenario it may be approached in practice when using a standard control treatment for which precise estimates are available from historical data. The maximum inflation of the type 1 error rate is substantially larger than derived by Proschan and Hunsberger (Biometrics 1995; 51:1315-1324) for design modifications applying balanced samples before and after the interim analysis. Corresponding upper limits for the maximum type 1 error rate are calculated for a number of situations arising from practical considerations (e.g. restricting the maximum sample size, not allowing sample size to decrease, allowing only increase in the sample size in the experimental treatment). The application is discussed for a motivating example.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21495058      PMCID: PMC4836563          DOI: 10.1002/sim.4230

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches.

Authors:  H H Müller; H Schäfer
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

2.  Adaptive sample size calculations in group sequential trials.

Authors:  W Lehmacher; G Wassmer
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

3.  A general statistical principle for changing a design any time during the course of a trial.

Authors:  Hans-Helge Müller; Helmut Schäfer
Journal:  Stat Med       Date:  2004-08-30       Impact factor: 2.373

Review 4.  Sample size re-estimation in clinical trials.

Authors:  Michael A Proschan
Journal:  Biom J       Date:  2009-04       Impact factor: 2.207

5.  Challenges and regulatory experiences with non-inferiority trial design without placebo arm.

Authors:  H M James Hung; Sue-Jane Wang; Robert O'Neill
Journal:  Biom J       Date:  2009-04       Impact factor: 2.207

6.  Exploring changes in treatment effects across design stages in adaptive trials.

Authors:  Tim Friede; Robin Henderson
Journal:  Pharm Stat       Date:  2009 Jan-Mar       Impact factor: 1.894

7.  A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.

Authors:  Nigel Stallard
Journal:  Stat Med       Date:  2010-02-26       Impact factor: 2.373

8.  Evaluation of experiments with adaptive interim analyses.

Authors:  P Bauer; K Köhne
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

9.  Designed extension of studies based on conditional power.

Authors:  M A Proschan; S A Hunsberger
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

10.  An approach to the conditional error rate principle with nuisance parameters.

Authors:  Georg Gutjahr; Werner Brannath; Peter Bauer
Journal:  Biometrics       Date:  2010-11-29       Impact factor: 2.571

View more
  9 in total

1.  Adaptive Budgets in Clinical Trials.

Authors:  Martin Posch; Peter Bauer
Journal:  Stat Biopharm Res       Date:  2013-04-04       Impact factor: 1.452

2.  Sample size reassessment for a two-stage design controlling the false discovery rate.

Authors:  Sonja Zehetmayer; Alexandra C Graf; Martin Posch
Journal:  Stat Appl Genet Mol Biol       Date:  2015-11

3.  Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.

Authors:  Alexandra C Graf; Peter Bauer; Ekkehard Glimm; Franz Koenig
Journal:  Biom J       Date:  2014-04-22       Impact factor: 2.207

4.  Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Authors:  Nigel Stallard; Cornelia Ursula Kunz; Susan Todd; Nicholas Parsons; Tim Friede
Journal:  Stat Med       Date:  2015-06-26       Impact factor: 2.373

5.  Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.

Authors:  Magdalena Żebrowska; Martin Posch; Dominic Magirr
Journal:  Stat Med       Date:  2015-12-23       Impact factor: 2.373

6.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

7.  Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.

Authors:  Per Broberg
Journal:  BMC Med Res Methodol       Date:  2013-07-19       Impact factor: 4.615

8.  Precision of maximum likelihood estimation in adaptive designs.

Authors:  Alexandra Christine Graf; Georg Gutjahr; Werner Brannath
Journal:  Stat Med       Date:  2015-10-12       Impact factor: 2.373

9.  A review and re-interpretation of a group-sequential approach to sample size re-estimation in two-stage trials.

Authors:  J Bowden; A Mander
Journal:  Pharm Stat       Date:  2014-04-02       Impact factor: 1.894

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.